Nanjing Novlead Biotechnology (NVLD HK): Synthetic Expert Call Transcript (31 Aug 2026)
Clinical Adoption Realities: While the projected 34.2% CAGR for the global instant-generation inhaled nitric oxide (iNO) market through 2030 is...
94 Views
IPO Databook: Nanjing Novlead Biotechnology (HK) - Aug 2026
Nanjing Novlead Biotechnology, incorporated in 2018, operates in the gas-based cardiopulmonary device market, focusing on inhaled nitric oxide...
115 Views
No more insights